VIR BIOTECHNOLOGY INC (VIR)
US92764N1028 - Common Stock
VIR BIOTECHNOLOGY INC
NASDAQ:VIR (12/20/2024, 8:00:01 PM)
After market: 7.39 +0.05 (+0.68%)7.34
-0.03 (-0.41%)
Company Profile
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 587 full-time employees. The company went IPO on 2019-10-11. The firm's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The firm's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. The company also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
Company Info
VIR BIOTECHNOLOGY INC
1800 Owens Street, Suite 900
San Francisco CALIFORNIA 94158
P: 14159064324
CEO: George Scangos
Employees: 587
Website: https://www.vir.bio/
VIR News
4 days ago - Vir Biotechnology, Inc.Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference10 days ago - Vir Biotechnology, Inc.Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta19 days ago - Market News VideoVIR Makes Bullish Cross Above Critical Moving Average19 days ago - Investor's Business DailyJanux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer PatientsAll 16 patients saw PSA declines of at least 50%. More than half reached a 90% decline in prostate-specific antigen levels.
19 days ago - ChartmillWondering what's happening in today's pre-market session? Stay tuned for the latest updates on stock movements.As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
20 days ago - ChartmillMonday's after hours session: top gainers and losersLet's have a look at what is happening on the US markets after the closing bell on Monday. Below you can find the top gainers and losers in today's after hours session.
VIR Twits
Here you can normally see the latest stock twits on VIR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
